N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Crohn's disease (CD) is a chronic recurrent intestinal inflammation involving the whole
digestive tract, with high disability rate, high surgical rate and high recurrent rate
postoperatively. Preventing postoperative recurrence in CD patients is an important clinical
problem needed urgent intervention. Azathioprine (AZA) and infliximab (IFX) effectively
prevent postoperative recurrence in CD patients, but the postoperative recurrence rate is
still as high as 41%. Oral supplement of n-3 polyunsaturated fatty acids (n-3 PUFA) owns the
advantages of high compliance and low economic cost. We aim to evaluate the effect of routine
treatment (AZA/IFX) combined with long-term dietary n-3PUFA on the prevention and treatment
of postoperative recurrence of CD, which help optimize the treatment strategy for the
prevention of postoperative recurrence.